Prospects not looking good yet The number of people who were tested for SARS-CoV-2 increased by 20% last week. The number of people who tested positive rose by 7%. The reproduction number also rose above 1.
Policy on coronavirus measures causes friction, but compliance is still high for now Compliance with the coronavirus measures in the Netherlands, such as the night-time curfew, working from home and avoiding crowds, is still high.
Decrease in meningococcal disease, outbreak of parrot fever in 2019 In the State of Infectious Diseases, RIVM provides an annual overview of the most important developments in relation to infectious diseases in the Netherlands.
More children vaccinated against mumps, measles, rubella and HPV The percentage of newborns participating in the immunisation programme targeting mumps, measles and rubella rose slightly over the past year.
Transfer models for harmful substances in animal feed online now RIVM and Wageningen Food Safety Research have made five feed-food transfer models available to calculate how many harmful substances in animal feed end up in animal-based foods.
Essential to keep a close eye on roll out of 5G The extent to which people are exposed to electromagnetic fields from individual 5G antennas and telephones is below the limits recommended by the European Union.
Control measures against the spread of Legionella from wastewater treatment plants Wastewater treatment plants (WWTPs) may spread Legionella via the air and cause pneumonia if people inhale them.
Mental care still the most expensive of all In 2011, 19.6 billion euros was spent on the treatment of mental disorders. This amounted to 22% of the total expenditure on health and welfare during that year.
Risks of eHealth technology RIVM and Nictiz have made an overview of the risks that eHealth applications may entail and how these risks can be controlled.
Key organisations unite to improve benefit and risk assessments of vaccines Leading organisations have joined forces to launch a unique project that will pave the way for a pan-European framework for rapidly assessing and communicating the benefits and risks of vaccines.